Donor acceptance rates hint at racial, gender bias in heart transplants: study

AdobeWhenapatientisgoingthroughend-stageheartfailure,thebesttreatmentistogetahearttransplant.Thebasi 1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint




explore

author：explore    Page View：1492
Franklin faces
Adobe

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

advertisement

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Primary care physicians play key roles in Alzheimer's management
Next article： Wildfire smoke exposes gaps in outdoor worker protections